Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FSHR | P23945 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899507 | 1.00 | BACE1 (0.35) | BACE1CYP19A1BACE2KDM4EALDH1A1 | |
| SCHEMBL2594 | 0.87 | BACE1 (0.36) | BACE1BACE2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2595 | 0.87 | BACE1 (0.36) | BACE1BACE2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL9923752 | 0.86 | BACE1 (0.34) | BACE1CYP19A1BACE2 | |
| SCHEMBL16378426 | 0.86 | BACE1 (0.34) | BACE1CYP19A1BACE2 | |
| SCHEMBL21981794 | 0.85 | BACE1 (0.31) | BACE1CYP19A1 | |
| SCHEMBL16341989 | 0.84 | AKR1B1 (0.36) | BACE1BACE2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL16341991 | 0.84 | AKR1B1 (0.36) | BACE1BACE2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL16341990 | 0.84 | AKR1B1 (0.36) | BACE1BACE2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL21981900 | 0.82 | CYP19A1 (0.34) | BACE1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2485590-B1 | PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8557826-B2 | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120148603-A1 | PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148603-A1 | PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, BACE2 | BACE1 1/4885CYP19A1 1192/4885BACE2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.